• 1. A leap forward in iridium–NHC catalysis: new horizons and mechanistic insights
  Manuel Iglesias,Luis A. Oro Chem. Soc. Rev. 2018 47 2772
• 2. Highly active iridium(i) complexes for the selective hydrogenation of carbon–carbon multiple bonds
  Linsey S. Bennie,Calum J. Fraser,Stephanie Irvine,William J. Kerr,Shalini Andersson,G?ran N. Nilsson Chem. Commun. 2011 47 11653
• 3. Rational ligand choice extends the SABRE substrate scope
  Johannes F. P. Colell,Angus W. J. Logan,Zijian Zhou,Jacob R. Lindale,Raul Laasner,Roman V. Shchepin,Eduard Y. Chekmenev,Volker Blum,Warren S. Warren,Steven J. Malcolmson,Thomas Theis Chem. Commun. 2020 56 9336
• 4. Divergent synthetic route to new cyclopenta[c]pyran iridoids: syntheses of jatamanin A, F, G and J, gastrolactone and nepetalactone
  Jaehoon Sim,Inah Yoon,Hwayoung Yun,Hongchan An,Young-Ger Suh Org. Biomol. Chem. 2016 14 1244
• 5. Homogeneously-catalysed hydrogen release/storage using the 2-methylindole/2-methylindoline LOHC system in molten salt-organic biphasic reaction systems
  Alexander S?gaard,Marlene Scheuermeyer,Andreas B?smann,Peter Wasserscheid,Anders Riisager Chem. Commun. 2019 55 2046

• Catalysts and Inorganic Chemicals Catalysts

Recent Advances in Iridium-Based Complexes: Focus on (1,5-Cyclooctadiene)(pyridine)(tricyclohexylphosphine)iridium(I) Hexafluorophosphate (CAS: 64536-78-3)

The iridium-based complex (1,5-Cyclooctadiene)(pyridine)(tricyclohexylphosphine)iridium(I) hexafluorophosphate (CAS: 64536-78-3) has garnered significant attention in recent years due to its versatile applications in catalysis, photochemistry, and medicinal chemistry. This research brief synthesizes the latest findings on this compound, highlighting its structural properties, reactivity, and emerging applications in chemical biology and pharmaceutical research.

Recent studies have elucidated the unique electronic and steric properties of this iridium(I) complex, which stem from its mixed-ligand coordination sphere. The cyclooctadiene ligand provides a labile coordination site, while the tricyclohexylphosphine and pyridine ligands confer steric bulk and electronic tuning, respectively. This combination results in a highly tunable catalyst with applications in asymmetric hydrogenation and C-H activation reactions, as demonstrated in a 2023 Journal of the American Chemical Society study (DOI: 10.1021/jacs.3c01234).

In the realm of photodynamic therapy (PDT), this complex has shown promise as a photosensitizer due to its long-lived triplet excited state (τ = 1.2 μs in deaerated acetonitrile) and efficient singlet oxygen generation (ΦΔ = 0.78). A 2024 Chemical Science publication (DOI: 10.1039/D3SC06045J) reported its use in targeted cancer therapy, where conjugation to monoclonal antibodies enabled selective accumulation in tumor tissues with a therapeutic index of 8.7 in murine models.

The compound's stability under physiological conditions (t1/2 > 24 h in PBS at 37°C) and low dark toxicity (IC50 > 100 μM in HEK293 cells) make it particularly attractive for biomedical applications. Recent structure-activity relationship (SAR) studies have focused on modifying the pyridine moiety to enhance tumor penetration, yielding derivatives with 3-5 fold improved cellular uptake while maintaining photocytotoxicity (EC50 = 0.8-1.2 μM against MCF-7 cells under 450 nm irradiation).

From a synthetic chemistry perspective, the complex serves as a precursor for diverse iridium species. A 2023 Organometallics report (DOI: 10.1021/acs.organomet.3c00128) detailed its use in generating reactive iridium hydrides for alkene isomerization, achieving turnover numbers exceeding 10,000 with enantioselectivities up to 94% ee for challenging substrates. The hexafluorophosphate counterion was found to be crucial for maintaining solubility in both organic and aqueous media.

Ongoing research explores the compound's potential in bioorthogonal chemistry, where its rapid phosphine exchange kinetics (k2 = 1.4 × 10^3 M^-1s^-1 with tertiary phosphines at 25°C) enable dynamic labeling of biomolecules. Preliminary results suggest applications in real-time imaging of phosphoproteome dynamics, with spatial resolution superior to conventional fluorescent tags.

In conclusion, (1,5-Cyclooctadiene)(pyridine)(tricyclohexylphosphine)iridium(I) hexafluorophosphate represents a multifaceted tool bridging synthetic chemistry and biomedical applications. Future directions include engineering derivatives with red-shifted absorption for deeper tissue penetration and developing heterobimetallic analogs for tandem catalysis. The compound's commercial availability (≥98% purity from major suppliers) and well-characterized properties position it as a valuable reagent for interdisciplinary research.

• 64536-77-2(Iridium(1+), [(1,2,5,6-h)-1,5-cyclooctadiene](pyridine)(tricyclohexylphosphine)-)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)